Medicina Baseada em Evidências

Revisão: Mapeamento dos conflitos de interesses.

8 Nov, 2021 | 12:27h

Mapping conflict of interests: scoping review – The BMJ

Comunicado de imprensa: Study reveals “extensive network” of industry ties with healthcare – BMJ

---

Editorial | Segurança e eficácia de antivirais contra SARS-CoV-2 – “Precisamos de evidências, não de otimismo.”

1 Nov, 2021 | 11:02h

Safety and efficacy of antivirals against SARS-CoV-2 – The BMJ

 

Comentário no Twitter

"Effective antivirals have an obvious appeal, but this must not cloud objective and transparent decision making." @dpsg108 and colleagues on the government's stockpiling of molnupiravir and PF-07321332+ritonavir for covid-19https://t.co/JUj1Y9op3P

— The BMJ (@bmj_latest) October 28, 2021

 

---

Exame clínico cardiovascular: a necessidade de uma abordagem baseada em evidências.

1 Nov, 2021 | 10:52h

Cardiovascular clinical examination: the need for an evidence-based approach – European Heart Journal

 

Comentário no Twitter

Which role for cardiac clinical examination today?
According to new cardiopulse, cardiac physical diagnosis shold be regarded as a science that can be learnt, rather than an art that can only be aspired to.https://t.co/oG1NJusXrS#cardiotwitter, @ESC_Journals, @escardio. pic.twitter.com/B9iUSv0gnj

— EHJ Editor-in-Chief (@ehj_ed) October 30, 2021

 

---

A fraude mais recente dos “predatory journals”: artigos contrabandeados e reformulados.

29 Out, 2021 | 14:31h

Predatory publishers’ latest scam: bootlegged and rebranded papers – Nature

Conteúdo relacionado: Predatory Journals: No Definition, No Defense

---

M-A | Dados de estudos randomizados mostraram que o infarto miocárdico não fatal não pode ser estabelecido com um bom substituto para a mortalidade cardiovascular e por todas as causas.

26 Out, 2021 | 11:19h

Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease: A Meta-analysis of Randomized Clinical Trials – JAMA Internal Medicine (gratuito por tempo limitado)

Editorial: Nonfatal Myocardial Infarction—Poor Surrogate for Mortality – JAMA Internal Medicine (gratuito por tempo limitado)

---

Diretriz de consenso sobre medidas para promover a equidade de autoria na publicação de pesquisas de parceiros internacionais.

25 Out, 2021 | 12:44h

Consensus statement on measures to promote equitable authorship in the publication of research from international partnerships – Anaesthesia

 

Comentário no Twitter

"Equitable authorship in international research partnerships"

In this consensus statement, we call on academic journals (& funders/employers) to ensure that an author reflexivity statement is submitted along with any manuscript from HIC-LMIC partnerships. https://t.co/IOKB04gSOm pic.twitter.com/musrVpCObz

— Ṣẹ̀yẹ Abímbọ́lá (@seyeabimbola) October 14, 2021

 

---

Opinião | É hora da Medicina Baseada em Evidências 2.0?

21 Out, 2021 | 11:23h

Is it time for Evidence-Based Medicine 2.0? – Centre for Evidence-Based Medicine

---

Opinião | Compreender os resultados de pesquisas, os resumos de evidências e sua aplicabilidade – e não uma avaliação crítica minuciosa – são habilidades fundamentais do currículo médico.

21 Out, 2021 | 11:22h

Understanding of research results, evidence summaries and their applicability—not critical appraisal—are core skills of medical curriculum – BMJ Evidence-Based Medicine

 

Comentário no Twitter

Is the critical appraisal of individual studies a core skill for clinicians? @KariTikkinen and @EBCPMcMaster argue that there are more important things for them to learn in order to apply #EBM in real life.

A thought-provoking piece in @BMJ_EBM 👌https://t.co/f6KvsRpHOw pic.twitter.com/FOf5ywT1bf

— Lucas Morin (@lucasmorin_eolc) October 20, 2021

 

---

Guia do usuário para a literatura médica: como interpretar e usar uma diretriz de prática clínica ou uma recomendação.

20 Out, 2021 | 11:53h

How to Interpret and Use a Clinical Practice Guideline or Recommendation: Users’ Guides to the Medical Literature – JAMA (gratuito por tempo limitado)

Entrevista com os autores: How to Interpret and Use a Clinical Practice Guideline

---

Consequências de longo prazo do mau uso de dados sobre ivermectina.

19 Out, 2021 | 12:52h

Long-term consequences of the misuse of ivermectin data – The Lancet Infectious Diseases

Conteúdos relacionados:

Ivermectin: How false science created a Covid ‘miracle’ drug.

Fraudulent ivermectin studies open up new battleground between science and misinformation.

The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.

Ivermectin: Cochrane’s most talked about review so far, ever. Why?

Flawed ivermectin preprint highlights challenges of COVID drug studies.

Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19.

Why was a major study on ivermectin for covid-19 just retracted?

RCT: Ivermectin does not prevent hospitalizations in patients with COVID-19.

Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”.

Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.

Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials

RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19

 

Comentário no Twitter

Ivermectin's data for Covid, checkered with inconsistencies, small/low quality clinical trials, and fraud, have long-term consequences for the drug's established and essential useshttps://t.co/NG6vpej8GP @TheLancetInfDis pic.twitter.com/Oz0FxUJetK

— Eric Topol (@EricTopol) October 18, 2021

 

---